eXoZymes Inc. filed a Form S-1 registration statement with the U.S. Securities and Exchange Commission on November 6, 2026, covering a proposed public offering of shares of common stock and accompanying purchase warrants, with Newbridge Securities Corporation serving as sole book-running manager.

Key Highlights

  • Offering structure: Each two shares of common stock are being offered together with one accompanying purchase warrant, according to the filing.
  • Warrant terms: The purchase warrants are exercisable immediately upon issuance, expire five years from the date of issuance, and will be issued in book-entry form through VStock Transfer, LLC as warrant agent.
  • Over-allotment option: The underwriter has been granted a 30-day option to purchase additional shares of common stock and purchase warrants at the public offering price, less underwriting discounts and commissions.
  • Underwriter expense reimbursement: The company will reimburse the underwriter for accountable expenses not to exceed $125,000.
  • Underwriter warrants: The registration statement registers for sale to the underwriter warrants exercisable for five years at an exercise price of 125% of the public offering price.
  • Company classification: eXoZymes is designated as a smaller reporting company and an emerging growth company, and has elected not to use the extended transition period for new or revised financial accounting standards.
  • Listing: Common stock is listed on The Nasdaq Capital Market under the symbol "EXOZ"; the company does not intend to apply for listing of the purchase warrants on any national securities exchange.

eXoZymes S-1 Registration: Structure of the Proposed Stock and Warrant Offering

eXoZymes Inc. (NASDAQ:EXOZ), a Nevada-incorporated company with principal executive offices at 750 Royal Oaks Drive, Suite 106, Monrovia, CA 91016, filed a preliminary Form S-1 registration statement on November 6, 2026. The filing covers an offering of an as-yet-unspecified number of shares of common stock together with purchase warrants, with share counts and pricing figures left as placeholders pending final determination. According to the filing, the actual combined public offering price per two shares of common stock and accompanying purchase warrant will be determined between the company and the underwriter at the time of pricing and "may be at a discount to this assumed offering price."

The filing states that the shares of common stock and the accompanying purchase warrants are "immediately separable and will be issued separately, but they can only be purchased together in this offering." The purchase warrants will be administered by VStock Transfer, LLC under a warrant agency agreement. Newbridge Securities Corporation is named as the sole book-running manager. The registration statement also registers warrants to be issued to the underwriter, exercisable for five years at 125% of the public offering price, with the underwriter carrying a 30-day over-allotment option.

The company disclosed that securities may not be sold until the registration statement becomes effective, and that the information in the preliminary prospectus "is not complete and may be changed." Risk factors are described beginning on page 13 of the prospectus and are also incorporated by reference from the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed March 30, 2026, and its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026. Legal counsel is provided by Spencer Fane LLP and Lucosky Brookman LLP.

What Was Disclosed

eXoZymes Inc. filed a preliminary S-1 registration statement on November 6, 2026, to register shares of common stock and purchase warrants for a proposed public offering. Key terms including share counts, exercise prices, and the combined offering price remain as placeholders pending final pricing.